Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

As of March 31, 2021, more than 265,000 people in Qatar had received both doses of the BNT162b2 vaccine. Viral sequencing indicated that 50.0% of infections from February 23 to March 18 were caused by B.1.351 and 44.5% by B.1.1.7. Vaccine effectiveness was 89.5% against the B.1.1.7 variant and 75.0%...

Full description

Saved in:

Bibliographic Details
Published in:	The New England journal of medicine Vol. 385; no. 2; pp. 187 - 189
Main Authors:	Abu-Raddad, Laith J, Chemaitelly, Hiam, Butt, Adeel A
Format:	Journal Article
Language:	English
Published:	United States Massachusetts Medical Society 08-07-2021
Subjects:	Coronavirus Coronaviruses Correspondence COVID-19 COVID-19 vaccines Genes Genomes Immunization Infections Infectious Disease mRNA Severe acute respiratory syndrome coronavirus 2 Vaccine efficacy Vaccines Qatar
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	As of March 31, 2021, more than 265,000 people in Qatar had received both doses of the BNT162b2 vaccine. Viral sequencing indicated that 50.0% of infections from February 23 to March 18 were caused by B.1.351 and 44.5% by B.1.1.7. Vaccine effectiveness was 89.5% against the B.1.1.7 variant and 75.0% against the B.1.351 variant. Effectiveness against severe, critical, or fatal disease was 97.4%.
Bibliography:	SourceType-Other Sources-1 ObjectType-Article-2 content type line 63 ObjectType-Correspondence-1 Members of the National Study Group for COVID-19 Vaccination are listed in the Supplementary Appendix, available with the full text of this letter at NEJM.org.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMc2104974